Detailed and consistent clinical and immunological monitoring of patients with Rheumatoid Arthritis who are treated with biological agents.

Detailed and consistent clinical and immunological monitoring of patients with Rheumatoid Arthritis who are treated with biological agents. - Clinical and immunological monitoring of rheumatoid arthritis patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39129

Enrollment

880

Registered

2009-03-24

Start date

2009-06-30

Completion date

Unknown

Last updated

2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheuma rheumatoid arthritis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Rheumatoid Arthritis according to ACR criteria (criteria van American College of Rheumatology) who start with biological treatment Age >18 years

Exclusion criteria

Exclusion criteria: Patients who understand the Dutch language insufficiently to appreciate the informed consent and to complete the Dutch questionnaires.

Design outcomes

Primary

Measure	Time frame
(short-term) Eular response to a specific biological agent	—

Secondary

Measure	Time frame
Side effects Long-term outcome based on radiographic joint damage Quality of life Effectiveness and cost-effectiveness of use of the developed prediction rule Fatigue and depressed mood Differences in response to therapy with biologicals between RA patients with a "Cold" or "Heat" type of symptom profile.	—

Countries

Netherlands

Outcome results